American Society of Hematology 2020 guidelines for sickle cell disease: management of acute and chronic pain

Amanda M Brandow, C Patrick Carroll, Susan Creary, Ronisha Edwards-Elliott, Jeffrey Glassberg, Robert W Hurley, Abdullah Kutlar, Mohamed Seisa, Jennifer Stinson, John J Strouse, Fouza Yusuf, William Zempsky, Eddy Lang, Amanda M Brandow, C Patrick Carroll, Susan Creary, Ronisha Edwards-Elliott, Jeffrey Glassberg, Robert W Hurley, Abdullah Kutlar, Mohamed Seisa, Jennifer Stinson, John J Strouse, Fouza Yusuf, William Zempsky, Eddy Lang

Abstract

Background: The management of acute and chronic pain for individuals living with sickle cell disease (SCD) is a clinical challenge. This reflects the paucity of clinical SCD pain research and limited understanding of the complex biological differences between acute and chronic pain. These issues collectively create barriers to effective, targeted interventions. Optimal pain management requires interdisciplinary care.

Objective: These evidence-based guidelines developed by the American Society of Hematology (ASH) are intended to support patients, clinicians, and other health care professionals in pain management decisions for children and adults with SCD.

Methods: ASH formed a multidisciplinary panel, including 2 patient representatives, that was thoroughly vetted to minimize bias from conflicts of interest. The Mayo Evidence-Based Practice Research Program supported the guideline development process, including updating or performing systematic reviews. Clinical questions and outcomes were prioritized according to importance for clinicians and patients. The Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach was used, including GRADE evidence-to-decision frameworks, to assess evidence and make recommendations, which were subject to public comment.

Results: The panel reached consensus on 18 recommendations specific to acute and chronic pain. The recommendations reflect a broad pain management approach, encompassing pharmacological and nonpharmacological interventions and analgesic delivery.

Conclusions: Because of low-certainty evidence and closely balanced benefits and harms, most recommendations are conditional. Patient preferences should drive clinical decisions. Policymaking, including that by payers, will require substantial debate and input from stakeholders. Randomized controlled trials and comparative-effectiveness studies are needed for chronic opioid therapy, nonopioid therapies, and nonpharmacological interventions.

Conflict of interest statement

Conflict-of-interest disclosure: All authors were members of the guideline panel or members of the systematic review team or both. As such, they completed a disclosure-of-interest form, which was reviewed by ASH and is available as Supplements 2 and 3.

© 2020 by The American Society of Hematology.

References

    1. Sil S, Cohen LL, Dampier C. Psychosocial and functional outcomes in youth with chronic sickle cell pain. Clin J Pain. 2016;32(6):527-533.
    1. Smith WR, Penberthy LT, Bovbjerg VE, et al. . Daily assessment of pain in adults with sickle cell disease. Ann Intern Med. 2008;148(2):94-101.
    1. Darbari DS, Ballas SK, Clauw DJ. Thinking beyond sickling to better understand pain in sickle cell disease. Eur J Haematol. 2014;93(2):89-95.
    1. Du S, Lin C, Tao YX. Updated mechanisms underlying sickle cell disease-associated pain. Neurosci Lett. 2019;712:134471.
    1. Tran H, Gupta M, Gupta K. Targeting novel mechanisms of pain in sickle cell disease. Hematology Am Soc Hematol Educ Program. 2017;2017:546-555.
    1. Schunemann HJ, Wiercioch W, Etxeandia I, et al. . Guidelines 2.0: systematic development of a comprehensive checklist for a successful guideline enterprise. CMAJ. 2014;186(3):E123-E142.
    1. Graham R, Mancher M, Wolman DM, Greenfield S, Steinberg E, eds. Clinical Practice Guidelines We Can Trust. Washington, DC: National Academies Press; 2011.
    1. Qaseem A, Forland F, Macbeth F, et al. ; Board of Trustees of the Guidelines International Network. Guidelines International Network: toward international standards for clinical practice guidelines. Ann Intern Med. 2012;156(7):525-531.
    1. Schünemann HJ, Al-Ansary LA, Forland F, et al. ; Board of Trustees of the Guidelines International Network. Guidelines International Network: principles for disclosure of interests and management of conflicts in guidelines. Ann Intern Med. 2015;163(7):548-553.
    1. Alonso-Coello P, Oxman AD, Moberg J, et al. ; GRADE Working Group. GRADE Evidence to Decision (EtD) frameworks: a systematic and transparent approach to making well informed healthcare choices. 2: Clinical practice guidelines. BMJ. 2016;353:i2089.
    1. Alonso-Coello P, Schünemann HJ, Moberg J, et al. ; GRADE Working Group. GRADE Evidence to Decision (EtD) frameworks: a systematic and transparent approach to making well informed healthcare choices. 1: Introduction. BMJ. 2016;353:i2016.
    1. Atkins D, Eccles M, Flottorp S, et al. ; GRADE Working Group. Systems for grading the quality of evidence and the strength of recommendations I: critical appraisal of existing approaches the GRADE Working Group. BMC Health Serv Res. 2004;4:38.
    1. Guyatt G, Oxman AD, Akl EA, et al. . GRADE guidelines: 1. Introduction-GRADE evidence profiles and summary of findings tables. J Clin Epidemiol. 2011;64(4):383-394.
    1. Guyatt GH, Oxman AD, Vist GE, et al. ; GRADE Working Group. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ. 2008;336(7650):924-926.
    1. Schunemann HJ, Best D, Vist G, Oxman AD, Group GW. Letters, numbers, symbols and words: how to communicate grades of evidence and recommendations. CMAJ. 2003;169(7):677-680.
    1. Schünemann HJ, Mustafa R, Brozek J, et al. ; GRADE Working Group. GRADE guidelines: 16. GRADE evidence to decision frameworks for tests in clinical practice and public health. J Clin Epidemiol. 2016;76:89-98.
    1. Guyatt GH, Alonso-Coello P, Schünemann HJ, et al. . Guideline panels should seldom make good practice statements: guidance from the GRADE Working Group. J Clin Epidemiol. 2016;80:3-7.
    1. Dampier C, Palermo TM, Darbari DS, Hassell K, Smith W, Zempsky W. AAPT diagnostic criteria for chronic sickle cell disease pain. J Pain. 2017;18(5):490-498.
    1. Headache Classification Committee of the International Headache Society. The International Classification of Headache Disorders, 3rd edition (beta version). Cephalalgia. 2013;33(9):629-808.
    1. Lo B, Fields M. Conflict of Interest in Medical Research, Education, and Practice. Washington, DC: National Academies Press; 2009.
    1. Akl EA, El-Hachem P, Abou-Haidar H, Neumann I, Schünemann HJ, Guyatt GH. Considering intellectual, in addition to financial, conflicts of interest proved important in a clinical practice guideline: a descriptive study. J Clin Epidemiol. 2014;67(11):1222-1228.
    1. Guyatt G, Akl EA, Hirsh J, et al. . The vexing problem of guidelines and conflict of interest: a potential solution. Ann Intern Med. 2010;152(11):738-741.
    1. Schünemann HJ, Osborne M, Moss J, et al. ; ATS Ethics and Conflict of Interest Committee and the Documents Development and Implementation Committee. An official American Thoracic Society Policy statement: managing conflict of interest in professional societies. Am J Respir Crit Care Med. 2009;180(6):564-580.
    1. Guyatt GH, Oxman AD, Kunz R, et al. . GRADE guidelines: 2. Framing the question and deciding on important outcomes. J Clin Epidemiol. 2011;64(4):395-400.
    1. Guyatt GH, Oxman AD, Kunz R, et al. ; GRADE Working Group. GRADE guidelines: 8. Rating the quality of evidence—indirectness. J Clin Epidemiol. 2011;64(12):1303-1310.
    1. Murad MH, Liem RI, Lang ES, et al. . 2019 sickle cell disease guidelines by the American Society of Hematology: methodology, challenges, and innovations. Blood Adv. 2019;3(23):3945-3950.
    1. Powars D, Lee S, Haywood LJ. What the emergency nurse needs to know about sickle cell disease. J Emerg Nurs. 1976;2(4):15-21.
    1. Linehan MS. Sickle cell anemia—the painful crisis. J Emerg Nurs. 1978;4(6):12-19.
    1. Selbst SM, Clark M. Analgesic use in the emergency department. Ann Emerg Med. 1990;19(9):1010-1013.
    1. Belgrave FZ, Molock SD. The role of depression in hospital admissions and emergency treatment of patients with sickle cell disease. J Natl Med Assoc. 1991;83(9):777-781.
    1. Sanders DY, Severance HW, Pollack CV Jr. Sickle cell vaso-occlusive pain crisis in adults: alternative strategies for management in the emergency department. South Med J. 1992;85(8):808-811.
    1. Todd KH, Green C, Bonham VL Jr, Haywood C Jr, Ivy E. Sickle cell disease related pain: crisis and conflict. J Pain. 2006;7(7):453-458.
    1. Zempsky WT. Treatment of sickle cell pain: fostering trust and justice. JAMA. 2009;302(22):2479-2480.
    1. Zempsky WT, Loiselle KA, McKay K, Lee BH, Hagstrom JN, Schechter NL. Do children with sickle cell disease receive disparate care for pain in the emergency department? J Emerg Med. 2010;39(5):691-695.
    1. Tanabe P, Silva S, Bosworth HB, et al. . A randomized controlled trial comparing two vaso-occlusive episode (VOE) protocols in sickle cell disease (SCD). Am J Hematol. 2018;93(2):159-168.
    1. Brandow AM, Nimmer M, Simmons T, et al. . Impact of emergency department care on outcomes of acute pain events in children with sickle cell disease. Am J Hematol. 2016;91(12):1175-1180.
    1. Patrick PA, Rosenthal BM, Iezzi CA, Brand DA. Timely pain management in the emergency department. J Emerg Med. 2015;48(3):267-273.
    1. Kavanagh PL, Sprinz PG, Wolfgang TL, et al. . Improving the management of vaso-occlusive episodes in the pediatric emergency department. Pediatrics. 2015;136(4):e1016-e1025.
    1. Tanabe P, Reddin C, Thornton VL, Todd KH, Wun T, Lyons JS. Emergency Department Sickle Cell Assessment of Needs and Strengths (ED-SCANS), a focus group and decision support tool development project. Acad Emerg Med. 2010;17(8):848-858.
    1. Field JJ, Ballas SK, Campbell CM, et al. . AAAPT diagnostic criteria for acute sickle cell disease pain. J Pain. 2019;20(7):746-759.
    1. Grisham JE, Vichinsky EP. Ketorolac versus meperidine in vaso-oclusive crisis: a study of safety and efficacy. Int J Pediatr Hematol Oncol. 1996;3:239-247.
    1. Beiter JL Jr, Simon HK, Chambliss CR, Adamkiewicz T, Sullivan K. Intravenous ketorolac in the emergency department management of sickle cell pain and predictors of its effectiveness. Arch Pediatr Adolesc Med. 2001;155(4):496-500.
    1. Perlin E, Finke H, Castro O, et al. . Enhancement of pain control with ketorolac tromethamine in patients with sickle cell vaso-occlusive crisis. Am J Hematol. 1994;46(1):43-47.
    1. Hardwick WE Jr, Givens TG, Monroe KW, King WD, Lawley D. Effect of ketorolac in pediatric sickle cell vaso-occlusive pain crisis. Pediatr Emerg Care. 1999;15(3):179-182.
    1. Bartolucci P, El Murr T, Roudot-Thoraval F, et al. . A randomized, controlled clinical trial of ketoprofen for sickle-cell disease vaso-occlusive crises in adults. Blood. 2009;114(18):3742-3747.
    1. Baddam S, Aban I, Hilliard L, Howard T, Askenazi D, Lebensburger JD. Acute kidney injury during a pediatric sickle cell vaso-occlusive pain crisis. Pediatr Nephrol. 2017;32(8):1451-1456.
    1. Griffin TC, McIntire D, Buchanan GR. High-dose intravenous methylprednisolone therapy for pain in children and adolescents with sickle cell disease. N Engl J Med. 1994;330(11):733-737.
    1. Lubega FA, DeSilva MS, Munube D, et al. . Low dose ketamine versus morphine for acute severe vaso occlusive pain in children: a randomized controlled trial. Scand J Pain. 2018;18(1):19-27.
    1. Zempsky WT, Loiselle KA, Corsi JM, Hagstrom JN. Use of low-dose ketamine infusion for pediatric patients with sickle cell disease-related pain: a case series. Clin J Pain. 2010;26(2):163-167.
    1. Tawfic QA, Faris AS, Kausalya R. The role of a low-dose ketamine-midazolam regimen in the management of severe painful crisis in patients with sickle cell disease. J Pain Symptom Manage. 2014;47(2):334-340.
    1. Gimovsky AC, Fritton K, Viscusi E, Roman A. Evaluating the use of ketamine for pain control with sickle cell crisis in pregnancy: a report of 2 cases. A A Pract. 2018;10(1):20-22.
    1. Sheehy KA, Lippold C, Rice AL, Nobrega R, Finkel JC, Quezado ZMN. Subanesthetic ketamine for pain management in hospitalized children, adolescents, and young adults: a single-center cohort study. J Pain Res. 2017;10:787-795.
    1. Schwenk ES, Viscusi ER, Buvanendran A, et al. . Consensus guidelines on the use of intravenous ketamine infusions for acute pain management from the American Society of Regional Anesthesia and Pain Medicine, the American Academy of Pain Medicine, and the American Society of Anesthesiologists. Reg Anesth Pain Med. 2018;43(5):456-466.
    1. Cohen SP, Bhatia A, Buvanendran A, et al. . Consensus guidelines on the use of intravenous ketamine infusions for chronic pain from the American Society of Regional Anesthesia and Pain Medicine, the American Academy of Pain Medicine, and the American Society of Anesthesiologists. Reg Anesth Pain Med. 2018;43(5):521-546.
    1. New T, Venable C, Fraser L, et al. . Management of refractory pain in hospitalized adolescents with sickle cell disease: changing from intravenous opioids to continuous infusion epidural analgesia. J Pediatr Hematol Oncol. 2014;36(6):e398-e402.
    1. Yaster M, Tobin JR, Billett C, Casella JF, Dover G. Epidural analgesia in the management of severe vaso-occlusive sickle cell crisis. Pediatrics. 1994;93(2):310-315.
    1. Abou-Setta AM, Beaupre LA, Rashiq S, et al. . Comparative effectiveness of pain management interventions for hip fracture: a systematic review. Ann Intern Med. 2011;155(4):234-245.
    1. Anim-Somuah M, Smyth RM, Cyna AM, Cuthbert A. Epidural versus non-epidural or no analgesia for pain management in labour. Cochrane Database Syst Rev. 2018;5:CD000331.
    1. Block BM, Liu SS, Rowlingson AJ, Cowan AR, Cowan JA Jr, Wu CL. Efficacy of postoperative epidural analgesia: a meta-analysis. JAMA. 2003;290(18):2455-2463.
    1. Okpala I. The management of crisis in sickle cell disease. Eur J Haematol. 1998;60(1):1-6.
    1. Carden MA, Patil P, Ahmad ME, Lam WA, Joiner CH, Morris CR. Variations in pediatric emergency medicine physician practices for intravenous fluid management in children with sickle cell disease and vaso-occlusive pain: a single institution experience. Pediatr Blood Cancer. 2018;65(1):e26742.
    1. Okomo U, Meremikwu MM. Fluid replacement therapy for acute episodes of pain in people with sickle cell disease. Cochrane Database Syst Rev. 2017;7:CD005406.
    1. Moody K, Abrahams B, Baker R, et al. . A randomized trial of yoga for children hospitalized with sickle cell vaso-occlusive crisis. J Pain Symptom Manage. 2017;53(6):1026-1034.
    1. Co LL, Schmitz TH, Havdala H, Reyes A, Westerman MP. Acupuncture: an evaluation in the painful crises of sickle cell anaemia. Pain. 1979;7(2):181-185.
    1. Wang WC, George SL, Wilimas JA. Transcutaneous electrical nerve stimulation treatment of sickle cell pain crises. Acta Haematol. 1988;80(2):99-102.
    1. Lu K, Cheng MC, Ge X, et al. . A retrospective review of acupuncture use for the treatment of pain in sickle cell disease patients: descriptive analysis from a single institution. Clin J Pain. 2014;30(9):825-830.
    1. Lemanek KL, Ranalli M, Lukens C. A randomized controlled trial of massage therapy in children with sickle cell disease. J Pediatr Psychol. 2009;34(10):1091-1096.
    1. Dobson CE, Byrne MW. Original research: using guided imagery to manage pain in young children with sickle cell disease. Am J Nurs. 2014;114(4):26-36; test 37, 47.
    1. Ezenwa MO, Yao Y, Engeland CG, et al. . A randomized controlled pilot study feasibility of a tablet-based guided audio-visual relaxation intervention for reducing stress and pain in adults with sickle cell disease. J Adv Nurs. 2016;72(6):1452-1463.
    1. Thomas JE, Koshy M, Patterson L, Dorn L, Thomas K. Management of pain in sickle cell disease using biofeedback therapy: a preliminary study. Biofeedback Self Regul. 1984;9(4):413-420.
    1. Agrawal AK, Robertson S, Litwin L, et al. . Virtual reality as complementary pain therapy in hospitalized patients with sickle cell disease. Pediatr Blood Cancer. 2019;66(2):e27525.
    1. Malloy KM, Milling LS. The effectiveness of virtual reality distraction for pain reduction: a systematic review. Clin Psychol Rev. 2010;30(8):1011-1018.
    1. Wittkopf PG, Lloyd DM, Johnson MI. Managing limb pain using virtual reality: a systematic review of clinical and experimental studies. Disabil Rehabil. 2019;41(26):3103-3117.
    1. Chan E, Foster S, Sambell R, Leong P. Clinical efficacy of virtual reality for acute procedural pain management: a systematic review and meta-analysis. PLoS One. 2018;13(7):e0200987.
    1. Shahrbanian S, Ma X, Korner-Bitensky N, Simmonds MJ. Scientific evidence for the effectiveness of virtual reality for pain reduction in adults with acute or chronic pain. Stud Health Technol Inform. 2009;144:40-43.
    1. Boitor M, Gelinas C, Richard-Lalonde M, Thombs BD. The effect of massage on acute postoperative pain in critically and acutely ill adults post-thoracic surgery: systematic review and meta-analysis of randomized controlled trials. Heart Lung. 2017;46(5):339-346.
    1. Sbruzzi G, Silveira SA, Silva DV, Coronel CC, Plentz RD. Transcutaneous electrical nerve stimulation after thoracic surgery: systematic review and meta-analysis of 11 randomized trials [in English, Portuguese]. Rev Bras Cir Cardiovasc. 2012;27(1):75-87.
    1. Li J, Song Y. Transcutaneous electrical nerve stimulation for postoperative pain control after total knee arthroplasty: a meta-analysis of randomized controlled trials. Medicine (Baltimore). 2017;96(37):e8036.
    1. Wu MS, Chen KH, Chen IF, et al. . The efficacy of acupuncture in post-operative pain management: a systematic review and meta-analysis. PLoS One. 2016;11(3):e0150367.
    1. Koch KL, Karafin MS, Simpson P, Field JJ. Intensive management of high-utilizing adults with sickle cell disease lowers admissions. Am J Hematol. 2015;90(3):215-219.
    1. Lanzkron S, Carroll CP, Hill P, David M, Paul N, Haywood C Jr. Impact of a dedicated infusion clinic for acute management of adults with sickle cell pain crisis. Am J Hematol. 2015;90(5):376-380.
    1. Molokie RE, Montminy C, Dionisio C, et al. . Opioid doses and acute care utilization outcomes for adults with sickle cell disease: ED versus acute care unit. Am J Emerg Med. 2018;36(1):88-92.
    1. Raphael JL, Kamdar A, Beavers MB, Mahoney DH, Mueller BU. Treatment of uncomplicated vaso-occlusive crises in children with sickle cell disease in a day hospital. Pediatr Blood Cancer. 2008;51(1):82-85.
    1. Benjamin LJ, Swinson GI, Nagel RL. Sickle cell anemia day hospital: an approach for the management of uncomplicated painful crises. Blood. 2000;95(4):1130-1136.
    1. Wright J, Bareford D, Wright C, et al. . Day case management of sickle pain: 3 years experience in a UK sickle cell unit. Br J Haematol. 2004;126(6):878-880.
    1. Adewoye AH, Nolan V, McMahon L, Ma Q, Steinberg MH. Effectiveness of a dedicated day hospital for management of acute sickle cell pain. Haematologica. 2007;92(6):854-855.
    1. Augier R, Jenkins S, Bortolusso Ali S, Tennant I, Williams-Johnson J, Reid M. A survey of the pain management of acute painful crisis among patients with sickle cell disease at two centres in Jamaica. West Indian Med J. 2014;63(3):252-257.
    1. Binding A, Ward R, Phua C, et al. . An innovative short-stay health care model for treatment of uncomplicated vaso-occlusive crisis in adult sickle cell disease patients in Canada to reduce emergency department utilization. CJEM. 2019;21(1):55-62.
    1. Dampier CD, Smith WR, Wager CG, et al. ; Sickle Cell Disease Clinical Research Network (SCDCRN). IMPROVE trial: a randomized controlled trial of patient-controlled analgesia for sickle cell painful episodes: rationale, design challenges, initial experience, and recommendations for future studies. Clin Trials. 2013;10(2):319-331.
    1. George JA, Lin EE, Hanna MN, et al. . The effect of intravenous opioid patient-controlled analgesia with and without background infusion on respiratory depression: a meta-analysis. J Opioid Manag. 2010;6(1):47-54.
    1. Hayes J, Dowling JJ, Peliowski A, Crawford MW, Johnston B. Patient-controlled analgesia plus background opioid infusion for postoperative pain in children: a systematic review and meta-analysis of randomized trials. Anesth Analg. 2016;123(4):991-1003.
    1. Horlocker TT, Burton AW, Connis RT, et al. ; American Society of Anesthesiologists Task Force on Neuraxial Opioids. Practice guidelines for the prevention, detection, and management of respiratory depression associated with neuraxial opioid administration. Anesthesiology. 2009;110(2):218-230.
    1. Delaney KM, Axelrod KC, Buscetta A, et al. . Leg ulcers in sickle cell disease: current patterns and practices. Hemoglobin. 2013;37(4):325-332.
    1. Blinder MA, Russel S, Barnes M. Prevalence of symptomatic avascular necrosis and the operative treatment in adult patients with sickle cell disease [abstract]. Blood. 2014;124(21). Abstract 1379.
    1. Brandalise SR, Assis R, Laranjeira ABA, Yunes JA, de Campos-Lima PO. Low-dose methotrexate in sickle-cell disease: a pilot study with rationale borrowed from rheumatoid arthritis. Exp Hematol Oncol. 2017;6:18.
    1. Odebiyi DO, Adigun OT, Kehinde MO. Effect of sodium salicylate iontophoresis in the management of hip pain in patients with sickle cell disease. Nig Q J Hosp Med. 2007;17(2):82-86.
    1. Cacciola E, Giustolisi R, Musso R, Longo A, Cacciola E. Antithrombin III concentrate for treatment of chronic leg ulcers in sickle cell-beta thalassemia: a pilot study. Ann Intern Med. 1989;111(6):534-536.
    1. Citrome L, Weiss-Citrome A. A systematic review of duloxetine for osteoarthritic pain: what is the number needed to treat, number needed to harm, and likelihood to be helped or harmed? Postgrad Med. 2012;124(1):83-93.
    1. Wang ZY, Shi SY, Li SJ, et al. . Efficacy and safety of duloxetine on osteoarthritis knee pain: a meta-analysis of randomized controlled trials. Pain Med. 2015;16(7):1373-1385.
    1. Myers J, Wielage RC, Han B, et al. . The efficacy of duloxetine, non-steroidal anti-inflammatory drugs, and opioids in osteoarthritis: a systematic literature review and meta-analysis. BMC Musculoskelet Disord. 2014;15:76.
    1. MacKay C, Clements N, Wong R, Davis AM. A systematic review of estimates of the minimal clinically important difference and patient acceptable symptom state of the Western Ontario and McMaster Universities Osteoarthritis Index in patients who underwent total hip and total knee replacement. Osteoarthritis Cartilage. 2019;27(10):1408-1419.
    1. Xu C, Gu K, Yasen Y, Hou Y. Efficacy and safety of celecoxib therapy in osteoarthritis: a meta-analysis of randomized controlled trials. Medicine (Baltimore). 2016;95(20):e3585.
    1. Zou K, Wong J, Abdullah N, et al. . Examination of overall treatment effect and the proportion attributable to contextual effect in osteoarthritis: meta-analysis of randomised controlled trials. Ann Rheum Dis. 2016;75(11):1964-1970.
    1. Jung SY, Jang EJ, Nam SW, et al. . Comparative effectiveness of oral pharmacologic interventions for knee osteoarthritis: a network meta-analysis. Mod Rheumatol. 2018;28(6):1021-1028.
    1. da Costa BR, Reichenbach S, Keller N, et al. . Effectiveness of non-steroidal anti-inflammatory drugs for the treatment of pain in knee and hip osteoarthritis: a network meta-analysis. Lancet. 2017;390(10090):e21-e33.
    1. Bannuru RR, Schmid CH, Kent DM, Vaysbrot EE, Wong JB, McAlindon TE. Comparative effectiveness of pharmacologic interventions for knee osteoarthritis: a systematic review and network meta-analysis. Ann Intern Med. 2015;162(1):46-54.
    1. Machado GC, Maher CG, Ferreira PH, et al. . Efficacy and safety of paracetamol for spinal pain and osteoarthritis: systematic review and meta-analysis of randomised placebo controlled trials. BMJ. 2015;350:h1225.
    1. Smith SR, Deshpande BR, Collins JE, Katz JN, Losina E. Comparative pain reduction of oral non-steroidal anti-inflammatory drugs and opioids for knee osteoarthritis: systematic analytic review. Osteoarthritis Cartilage. 2016;24(6):962-972.
    1. Gregori D, Giacovelli G, Minto C, et al. . Association of pharmacological treatments with long-term pain control in patients with knee osteoarthritis: a systematic review and meta-analysis. JAMA. 2018;320(24):2564-2579.
    1. Lin J, Zhang W, Jones A, Doherty M. Efficacy of topical non-steroidal anti-inflammatory drugs in the treatment of osteoarthritis: meta-analysis of randomised controlled trials. BMJ. 2004;329(7461):324.
    1. Bridge JA, Iyengar S, Salary CB, et al. . Clinical response and risk for reported suicidal ideation and suicide attempts in pediatric antidepressant treatment: a meta-analysis of randomized controlled trials. JAMA. 2007;297(15):1683-1696.
    1. Weir MR. Renal effects of nonselective NSAIDs and coxibs. Cleve Clin J Med. 2002;69(suppl 1):SI53-SI58.
    1. Perneger TV, Whelton PK, Klag MJ. Risk of kidney failure associated with the use of acetaminophen, aspirin, and nonsteroidal antiinflammatory drugs. N Engl J Med. 1994;331(25):1675-1679.
    1. Nelson DA, Marks ES, Deuster PA, O’Connor FG, Kurina LM. Association of nonsteroidal anti-inflammatory drug prescriptions with kidney disease among active young and middle-aged adults. JAMA Netw Open. 2019;2(2):e187896.
    1. Haag MD, Bos MJ, Hofman A, Koudstaal PJ, Breteler MM, Stricker BH. Cyclooxygenase selectivity of nonsteroidal anti-inflammatory drugs and risk of stroke. Arch Intern Med. 2008;168(11):1219-1224.
    1. Massó González EL, Patrignani P, Tacconelli S, García Rodríguez LA. Variability among nonsteroidal antiinflammatory drugs in risk of upper gastrointestinal bleeding. Arthritis Rheum. 2010;62(6):1592-1601.
    1. Osunkwo I, Ziegler TR, Alvarez J, et al. . High dose vitamin D therapy for chronic pain in children and adolescents with sickle cell disease: results of a randomized double blind pilot study. Br J Haematol. 2012;159(2):211-215.
    1. Schlaeger JM, Molokie RE, Yao Y, et al. . Management of sickle cell pain using pregabalin: a pilot study. Pain Manag Nurs. 2017;18(6):391-400.
    1. Jerrell JM, Tripathi A, Stallworth JR. Pain management in children and adolescents with sickle cell disease. Am J Hematol. 2011;86(1):82-84.
    1. Cooper TE, Wiffen PJ, Heathcote LC, et al. . Antiepileptic drugs for chronic non-cancer pain in children and adolescents. Cochrane Database Syst Rev. 2017;8(8):CD012536.
    1. Häuser W, Urrútia G, Tort S, Uçeyler N, Walitt B. Serotonin and noradrenaline reuptake inhibitors (SNRIs) for fibromyalgia syndrome. Cochrane Database Syst Rev. 2013;(1):CD010292.
    1. Häuser W, Wolfe F, Tölle T, Uçeyler N, Sommer C. The role of antidepressants in the management of fibromyalgia syndrome: a systematic review and meta-analysis. CNS Drugs. 2012;26(4):297-307.
    1. Derry S, Cording M, Wiffen PJ, Law S, Phillips T, Moore RA. Pregabalin for pain in fibromyalgia in adults. Cochrane Database Syst Rev. 2016;9:CD011790.
    1. Arnold LM, Schikler KN, Bateman L, et al. ; Pregabalin Adolescent Fibromyalgia Study Group. Safety and efficacy of pregabalin in adolescents with fibromyalgia: a randomized, double-blind, placebo-controlled trial and a 6-month open-label extension study. Pediatr Rheumatol Online J. 2016;14(1):46.
    1. US Food and Drug Administration. Suicidality in children and adolescents being treated with antidepressant medications. Available at: . Accessed 12 August 2019.
    1. Schatz J, Schlenz AM, McClellan CB, et al. . Changes in coping, pain, and activity after cognitive-behavioral training: a randomized clinical trial for pediatric sickle cell disease using smartphones. Clin J Pain. 2015;31(6):536-547.
    1. Barakat LP, Schwartz LA, Salamon KS, Radcliffe J. A family-based randomized controlled trial of pain intervention for adolescents with sickle cell disease. J Pediatr Hematol Oncol. 2010;32(7):540-547.
    1. Thomas VJ, Dixon AL, Milligan P, Thomas N. Cognitive-behaviour therapy for the management of sickle cell disease pain: an evaluation of a community-based intervention. Br J Health Psychol. 1999;4(3):209-229.
    1. Gil KM, Carson JW, Sedway JA, Porter LS, Schaeffer JJ, Orringer E. Follow-up of coping skills training in adults with sickle cell disease: analysis of daily pain and coping practice diaries. Health Psychol. 2000;19(1):85-90.
    1. Dobson C. Outcome results of self-efficacy in children with sickle disease pain who were trained to use guided imagery. Appl Nurs Res. 2015;28(4):384-390.
    1. Dinges DF, Whitehouse WG, Orne EC, et al. . Self-hypnosis training as an adjunctive treatment in the management of pain associated with sickle cell disease. Int J Clin Exp Hypn. 1997;45(4):417-432.
    1. Myrvik MP, Campbell AD, Butcher JL. Single-session biofeedback-assisted relaxation training in children with sickle cell disease. J Pediatr Hematol Oncol. 2012;34(5):340-343.
    1. Matheve T, Brumagne S, Timmermans AAA. The effectiveness of technology-supported exercise therapy for low back pain: a systematic review. Am J Phys Med Rehabil. 2017;96(5):347-356.
    1. Richmond H, Hall AM, Copsey B, et al. . The effectiveness of cognitive behavioural treatment for non-specific low back pain: a systematic review and meta-analysis. PLoS One. 2015;10(8):e0134192.
    1. Bernardy K, Füber N, Köllner V, Häuser W. Efficacy of cognitive-behavioral therapies in fibromyalgia syndrome - a systematic review and metaanalysis of randomized controlled trials. J Rheumatol. 2010;37(10):1991-2005.
    1. Bawa FL, Mercer SW, Atherton RJ, et al. . Does mindfulness improve outcomes in patients with chronic pain? Systematic review and meta-analysis. Br J Gen Pract. 2015;65(635):e387-e400.
    1. Sielski R, Rief W, Glombiewski JA. Efficacy of biofeedback in chronic back pain: a meta-analysis. Int J Behav Med. 2017;24(1):25-41.
    1. Myers CD, Robinson ME, Guthrie TH, Lamp SP, Lottenberg R. Adjunctive approaches for sickle cell chronic pain. Altern Health Pract. 1999;5:203-212.
    1. Cozzi L, Tryon WW, Sedlacek K. The effectiveness of biofeedback-assisted relaxation in modifying sickle cell crises. Biofeedback Self Regul. 1987;12(1):51-61.
    1. Li YH, Wang FY, Feng CQ, Yang XF, Sun YH. Massage therapy for fibromyalgia: a systematic review and meta-analysis of randomized controlled trials. PLoS One. 2014;9(2):e89304.
    1. Rubinstein SM, van Middelkoop M, Kuijpers T, et al. . A systematic review on the effectiveness of complementary and alternative medicine for chronic non-specific low-back pain. Eur Spine J. 2010;19(8):1213-1228.
    1. Yuan QL, Guo TM, Liu L, Sun F, Zhang YG. Traditional Chinese medicine for neck pain and low back pain: a systematic review and meta-analysis. PLoS One. 2015;10(2):e0117146.
    1. Yuan J, Purepong N, Kerr DP, Park J, Bradbury I, McDonough S. Effectiveness of acupuncture for low back pain: a systematic review. Spine. 2008;33(23):E887-E900.
    1. Lam M, Galvin R, Curry P. Effectiveness of acupuncture for nonspecific chronic low back pain: a systematic review and meta-analysis. Spine. 2013;38(24):2124-2138.
    1. Wells C, Kolt GS, Marshall P, Hill B, Bialocerkowski A. The effectiveness of Pilates exercise in people with chronic low back pain: a systematic review. PLoS One. 2014;9(7):e100402.
    1. Bidonde J, Busch AJ, Bath B, Milosavljevic S. Exercise for adults with fibromyalgia: an umbrella systematic review with synthesis of best evidence. Curr Rheumatol Rev. 2014;10(1):45-79.
    1. Häuser W, Klose P, Langhorst J, et al. . Efficacy of different types of aerobic exercise in fibromyalgia syndrome: a systematic review and meta-analysis of randomised controlled trials. Arthritis Res Ther. 2010;12(3):R79.
    1. Searle A, Spink M, Ho A, Chuter V. Exercise interventions for the treatment of chronic low back pain: a systematic review and meta-analysis of randomised controlled trials. Clin Rehabil. 2015;29(12):1155-1167.
    1. van Middelkoop M, Rubinstein SM, Kuijpers T, et al. . A systematic review on the effectiveness of physical and rehabilitation interventions for chronic non-specific low back pain. Eur Spine J. 2011;20(1):19-39.
    1. Macedo LG, Maher CG, Latimer J, McAuley JH. Motor control exercise for persistent, nonspecific low back pain: a systematic review. Phys Ther. 2009;89(1):9-25.
    1. Smith BE, Littlewood C, May S. An update of stabilisation exercises for low back pain: a systematic review with meta-analysis. BMC Musculoskelet Disord. 2014;15:416.
    1. Wang XQ, Zheng JJ, Yu ZW, et al. . A meta-analysis of core stability exercise versus general exercise for chronic low back pain. PLoS One. 2012;7(12):e52082.
    1. Von Korff M, Dublin S, Walker RL, et al. . The impact of opioid risk reduction initiatives on high-dose opioid prescribing for patients on chronic opioid therapy. J Pain. 2016;17(1):101-110.
    1. Turner JA, Shortreed SM, Saunders KW, LeResche L, Thielke S, Von Korff M. Does association of opioid use with pain and function differ by fibromyalgia or widespread pain status? Pain. 2016;157(10):2208-2216.
    1. Els C, Jackson TD, Hagtvedt R, et al. . High-dose opioids for chronic non-cancer pain: an overview of Cochrane reviews. Cochrane Database Syst Rev. 2017;10(10):CD012299.
    1. Busse JW, Wang L, Kamaleldin M, et al. . Opioids for chronic noncancer pain: a systematic review and meta-analysis. JAMA. 2018;320(23):2448-2460.
    1. Chou R, Turner JA, Devine EB, et al. . The effectiveness and risks of long-term opioid therapy for chronic pain: a systematic review for a National Institutes of Health Pathways to Prevention Workshop. Ann Intern Med. 2015;162(4):276-286.
    1. Noble M, Treadwell JR, Tregear SJ, et al. . Long-term opioid management for chronic noncancer pain. Cochrane Database Syst Rev. 2010;2010(1):CD006605.
    1. Cooper TE, Fisher E, Gray AL, et al. . Opioids for chronic non-cancer pain in children and adolescents. Cochrane Database Syst Rev. 2017;7(7):CD012538.
    1. Gulur P, Williams L, Chaudhary S, Koury K, Jaff M. Opioid tolerance—a predictor of increased length of stay and higher readmission rates. Pain Physician. 2014;17(4):E503-E507.
    1. Gomes T, Redelmeier DA, Juurlink DN, Dhalla IA, Camacho X, Mamdani MM. Opioid dose and risk of road trauma in Canada: a population-based study. JAMA Intern Med. 2013;173(3):196-201.
    1. Li L, Setoguchi S, Cabral H, Jick S. Opioid use for noncancer pain and risk of myocardial infarction amongst adults. J Intern Med. 2013;273(5):511-526.
    1. Li L, Setoguchi S, Cabral H, Jick S. Opioid use for noncancer pain and risk of fracture in adults: a nested case-control study using the general practice research database. Am J Epidemiol. 2013;178(4):559-569.
    1. Deyo RA, Smith DH, Johnson ES, et al. . Prescription opioids for back pain and use of medications for erectile dysfunction. Spine. 2013;38(11):909-915.
    1. Dunn KM, Saunders KW, Rutter CM, et al. . Opioid prescriptions for chronic pain and overdose: a cohort study. Ann Intern Med. 2010;152(2):85-92.
    1. Gomes T, Mamdani MM, Dhalla IA, Paterson JM, Juurlink DN. Opioid dose and drug-related mortality in patients with nonmalignant pain. Arch Intern Med. 2011;171(7):686-691.
    1. Edlund MJ, Martin BC, Russo JE, DeVries A, Braden JB, Sullivan MD. The role of opioid prescription in incident opioid abuse and dependence among individuals with chronic noncancer pain: the role of opioid prescription. Clin J Pain. 2014;30(7):557-564.
    1. Ruta NS, Ballas SK. The opioid drug epidemic and sickle cell disease: guilt by association. Pain Med. 2016;17(10):1793-1798.
    1. Dasgupta N, Funk MJ, Proescholdbell S, Hirsch A, Ribisl KM, Marshall S. Cohort study of the impact of high-dose opioid analgesics on overdose mortality [published correction appears in Pain Med. 2016;17(4):797-798]. Pain Med. 2016;17(1):85-98.
    1. Murphy L, Babaei-Rad R, Buna D, et al. . Guidance on opioid tapering in the context of chronic pain: evidence, practical advice and frequently asked questions. Can Pharm J. 2018;151(2):114-120.
    1. Darnall BD, Ziadni MS, Stieg RL, Mackey IG, Kao MC, Flood P. Patient-centered prescription opioid tapering in community outpatients with chronic pain. JAMA Intern Med. 2018;178(5):707-708.
    1. Sullivan MD, Turner JA, DiLodovico C, D’Appollonio A, Stephens K, Chan YF. Prescription opioid taper support for outpatients with chronic pain: a randomized controlled trial. J Pain. 2017;18(3):308-318.
    1. Berna C, Kulich RJ, Rathmell JP. Tapering long-term opioid therapy in chronic noncancer pain: evidence and recommendations for everyday practice. Mayo Clin Proc. 2015;90(6):828-842.
    1. Murphy JL, Clark ME, Banou E. Opioid cessation and multidimensional outcomes after interdisciplinary chronic pain treatment. Clin J Pain. 2013;29(2):109-117.
    1. Haroutiunian S, Donaldson G, Yu J, Lipman AG. Development and validation of shortened, restructured Treatment Outcomes in Pain Survey instrument (the S-TOPS) for assessment of individual pain patients’ health-related quality of life. Pain. 2012;153(8):1593-1601.
    1. HealthMeasures. Pain domains. Available at: . Accessed 1 September 2019.
    1. Black RA, McCaffrey SA, Villapiano AJ, Jamison RN, Butler SF. Development and validation of an eight-item brief form of the SOAPP-R (SOAPP-8). Pain Med. 2018;19(10):1982-1987.
    1. McCaffrey SA, Black RA, Villapiano AJ, Jamison RN, Butler SF. Development of a brief version of the Current Opioid Misuse Measure (COMM): the COMM-9. Pain Med. 2019;20(1):113-118.
    1. Jamison RN, Martel MO, Huang CC, Jurcik D, Edwards RR. Efficacy of the opioid compliance checklist to monitor chronic pain patients receiving opioid therapy in primary care. J Pain. 2016;17(4):414-423.
    1. Jamison RN, Edwards RR. Risk factor assessment for problematic use of opioids for chronic pain. Clin Neuropsychol. 2013;27(1):60-80.
    1. Kaye AD, Jones MR, Kaye AM, et al. . Prescription opioid abuse in chronic pain: an updated review of opioid abuse predictors and strategies to curb opioid abuse (part 2). Pain Physician. 2017;20(2S):S111-S133.
    1. Charache S, Terrin ML, Moore RD, et al. ; Investigators of the Multicenter Study of Hydroxyurea in Sickle Cell Anemia. Effect of hydroxyurea on the frequency of painful crises in sickle cell anemia. N Engl J Med. 1995;332(20):1317-1322.
    1. Niihara Y, Miller ST, Kanter J, et al. ; Investigators of the Phase 3 Trial of l-Glutamine in Sickle Cell Disease. A phase 3 trial of l-glutamine in sickle cell disease. N Engl J Med. 2018;379(3):226-235.
    1. Ataga KI, Kutlar A, Kanter J, et al. . Crizanlizumab for the prevention of pain crises in sickle cell disease. N Engl J Med. 2017;376(5):429-439.
    1. National Heart, Lung, and Blood Institute Expert Panel. Evidence-Based Management of Sickle Cell Disease: Expert Panel Report 2014. Bethesda, MD: National Institutes of Health; 2014.
    1. Alvarez O, Yovetich NA, Scott JP, et al. ; Investigators of the Stroke With Transfusions Changing to Hydroxyurea Clinical Trial (SWiTCH). Pain and other non-neurological adverse events in children with sickle cell anemia and previous stroke who received hydroxyurea and phlebotomy or chronic transfusions and chelation: results from the SWiTCH clinical trial. Am J Hematol. 2013;88(11):932-938.
    1. Kalff A, Dowsing C, Grigg A. The impact of a regular erythrocytapheresis programme on the acute and chronic complications of sickle cell disease in adults. Br J Haematol. 2010;149(5):768-774.
    1. Koshy M, Burd L, Wallace D, Moawad A, Baron J. Prophylactic red-cell transfusions in pregnant patients with sickle cell disease. A randomized cooperative study. N Engl J Med. 1988;319(22):1447-1452.
    1. DeBaun MR, Gordon M, McKinstry RC, et al. . Controlled trial of transfusions for silent cerebral infarcts in sickle cell anemia. N Engl J Med. 2014;371(8):699-710.
    1. Miller ST, Wright E, Abboud M, et al. ; STOP Investigators. Impact of chronic transfusion on incidence of pain and acute chest syndrome during the Stroke Prevention Trial (STOP) in sickle-cell anemia. J Pediatr. 2001;139(6):785-789.
    1. Hilliard LM, Kulkarni V, Sen B, et al. . Red blood cell transfusion therapy for sickle cell patients with frequent painful events. Pediatr Blood Cancer. 2018;65(12):e27423.
    1. Styles LA, Vichinsky E. Effects of a long-term transfusion regimen on sickle cell-related illnesses. J Pediatr. 1994;125(6 pt 1):909-911.
    1. Yawn BP, Buchanan GR, Afenyi-Annan AN, et al. . Management of sickle cell disease: summary of the 2014 evidence-based report by expert panel members [published corrections appear in JAMA. 2014;312(18):1932, JAMA. 2015;313(7):729]. JAMA. 2014;312(10):1033-1048.
    1. Benjamin LJ, Dampier CD, Jacox AK, et al. . Guideline for the Management of Acute and Chronic Pain in Sickle Cell Disease. Glenview, IL: American Pain Society; 1999.
    1. Center for Clinical Practice at NICE. Sickle Cell Acute Painful Episode: Management of an Acute Painful Sickle Cell Episode in Hospital. Manchester, United Kingdom: National Institute for Health and Clinical Excellence. 2012.
    1. Dowell D, Haegerich TM, Chou R. CDC guideline for prescribing opioids for chronic pain—United States, 2016. JAMA. 2016;315(15):1624-1645.
    1. American Society of Hematology. CDC issues key clarification on guideline for prescribing opioids for chronic pain. . Accessed 10 September 2019.
    1. Schünemann HJ, Wiercioch W, Brozek J, et al. . GRADE Evidence to Decision (EtD) frameworks for adoption, adaptation, and de novo development of trustworthy recommendations: GRADE-ADOLOPMENT. J Clin Epidemiol. 2017;81:101-110.

Source: PubMed

Szponzorok és közreműködők

Egészségi állapot

Kábítószer-beavatkozások

3
Iratkozz fel